株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

世界のキナーゼ阻害剤市場:新興市場

Kinase Inhibitors: Global Markets -- Focus on Emerging Markets

発行 BCC Research 商品コード 246348
出版日 ページ情報 英文 119 Pages
即納可能
価格
本日の銀行送金レート: 1USD=114.71円で換算しております。
Back to Top
世界のキナーゼ阻害剤市場:新興市場 Kinase Inhibitors: Global Markets -- Focus on Emerging Markets
出版日: 2012年06月30日 ページ情報: 英文 119 Pages
概要

世界のキナーゼ阻害剤市場は、2010年に281億米ドルに達し、2011年には291億米ドル近い市場規模を記録しました。今後は6.7%の年平均成長率(CAGR)で推移し、2016年には402億米ドルの市場規模に達すると予測されています。新興地域のキナーゼ阻害剤市場は、2010年に29億米ドル、また、2011年には41億米ドルとなりました。同市場は今後、CAGR15.2%で拡大し、2016年には84億米ドルに達する見通しです。新興地域の抗体キナーゼ阻害剤部門は、2010年に18億米ドル、2011年には21億米ドルとなりました。同市場は今後、CAGR15.2%で拡大し、2016年には43億米ドルに達する見通しです。

当レポートでは、世界のキナーゼ阻害剤市場、特に新興市場の現状と見通しについて調査分析し、主要製品とその製造・供給事業者、新たな製品の開発動向、製品区分・用途別の市場規模実績・予測(〜2016年)、製品区分別の市場シェア、特許の状況、将来の方向性、主要企業のプロファイルなどをまとめ、概略以下の構成でお届けします。

第1章 イントロダクション

第2章 サマリー

第3章 概要

  • 定義
  • 酵素阻害薬
  • キナーゼ阻害薬

第4章 法規制的側面

  • 市場のリーダーとその製品

第5章 新たな開発動向

  • (レセプター)チロシンキナーゼ阻害薬(TKI)
  • (非レセプター)チロシンキナーゼ阻害薬(TKI)
  • マルチキナーゼ阻害薬
  • セリン・スレオニンキナーゼ阻害薬
  • その他

第6章 世界市場

  • 市場分析
    • チロシンキナーゼ阻害薬
    • セリン・スレオニンキナーゼ阻害薬
    • モノクローナル抗体キナーゼ阻害薬
  • 市場シェア
    • レセプターチロシンキナーゼ阻害薬
    • 非レセプターチロシンキナーゼ阻害薬
    • マルチターゲットキナーゼ阻害薬
    • セリン・スレオニンキナーゼ阻害薬
    • モノクローナル抗体キナーゼ阻害薬
  • 市場アプリケーション
    • 市場収益
    • 抗腫瘍薬
    • 免疫抑制剤
    • 加齢黄斑変性(AMD)
    • 市場シェア

第7章 新興市場

  • 市場分析
    • チロシンキナーゼ阻害薬
    • セリン・スレオニンキナーゼ阻害薬
    • モノクローナル抗体キナーゼ阻害薬
  • 主要企業の市場シェア
    • レセプターチロシンキナーゼ阻害薬
    • 非レセプターチロシンキナーゼ阻害薬
    • マルチターゲットキナーゼ阻害薬
    • セリン・スレオニンキナーゼ阻害薬
    • 抗体キナーゼ阻害薬
  • 市場アプリケーション
    • 市場収益
    • 抗腫瘍薬
    • 免疫抑制剤
    • 加齢黄斑変性(AMD)
    • 市場シェア

第8章 特許分析

第9章 現状

  • 癌とキナーゼ阻害薬
  • 複数の単一キナーゼ阻害薬 vs ひとつのマルチキナーゼ阻害薬
    • 効果
    • 耐性
    • 薬物動態
    • 腫瘍微小環境
    • 毒性
  • 将来の方向性

第10章 企業プロファイル

  • ABBOTT LABORATORIES
  • AMGEN INC.
  • ARQULE, INC.
  • ARRAY BIOPHARMA
  • ASTRAZENECA
  • AVEO PHARMACEUTICALS, INC.
  • BAYER AG
  • BRISTOL-MYERS SQUIBB
  • BOEHRINGER INGELHEIM
  • CYTRX CORPORATION
  • エーザイ
  • ETON BIOSCIENCE, INC.
  • EXELIXIS, INC.
  • GLAXOSMITHKLINE
  • MERCK SERONO SA
  • NOVARTIS INTERNATIONAL AG
  • OSI PHARMACEUTICALS LLC
  • PFIZER
  • ROCHE GROUP
  • S*BIO PTE LTD
  • SANOFI-AVENTIS
  • 武田薬品工業

第11章 用語

図表

目次
Product Code: BIO111A

The global kinase inhibitors market reached $28.1 billion in 2010 and nearly $29.1 billion in 2011. The market is expected to reach $40.2 billion by 2016, a compound annual growth rate (CAGR) of 6.7%.

The emerging markets segment for kinase inhibitors reached $2.9 billion in 2010 and $4.1 billion in 2011. The market is expected to reach $8.4 billion by 2016, a CAGR of 15.2%.

The emerging markets segment for antibody kinase inhibitors reached $1.8 billion in 2010 and $2.1 billion in 2011. The market is expected to reach $4.3 billion by 2016, a CAGR of 15.2%.

SUMMARY FIGURE
GLOBAL REVENUE OF KINASE INHIBITORS MARKET, 2009-2016
($ MILLIONS)

Source: BCC Research

STUDY OBJECTIVES

BCC's goal in conducting this study is to provide an overview of the current and future characteristics of the global market for kinase inhibitors. The key objective is to present a comprehensive analysis and the future direction of kinase inhibitors to provide an important tool for the usage of these types of enzyme inhibitors.

This report explores present and future strategies within the kinase inhibitors market, which includes tyrosine inhibitors, multi-target kinase inhibitors, serine/ threonine inhibitors and monoclonal antibody kinase inhibitors. The direction of the market, its setbacks and the needs of the market are discussed in this report. The classifications, comparisons and usage of these types of enzyme inhibitors are also examined in the report.

A detailed analysis of the kinase inhibitors industry structure has been conducted. Revenues are broken down by region. Sales figures are estimated for the five-year period from 2011 through 2016.

Applications for kinase inhibitors are also discussed separately in the report, with emphasis on the usage of the inhibitors in therapeutic categories and various disease sectors. The report also covers significant patents and a summary of patents awarded in each category.

SCOPE OF THE STUDY

The scope of this study encompasses kinase inhibitors in pharmaceutical and biotechnology markets. BCC analyzes each market and its applications, regulatory environment, technology, market projections and market share. Technological issues include the latest trends and developments. The emerging market for enzyme inhibitors includes India, China, Japan, South Korea, Taiwan, Canada, Africa, Australia and New Zealand and others countries.

ABOUT THE AUTHOR

A team of professionals in the biotechnology industry carried out this study. The project manager is Shalini S. Dewan, who holds a master's degree in pharmaceutical chemistry and has over 14 years of industry experience. Among the research topics she has covered are studies on compounds of potential pharmaceutical interest from ibuprofen and 2-naphthyl acetic acid. Shalini was awarded a Gold Medal by the Prime Minister of India for her work and has worked with top companies in India and in the U.S.

Table of Contents

Kinase Inhibitors: Global Markets -- Focus on Emerging Markets

Chapter - 1: INTRODUCTION - Complimentary

  • STUDY OBJECTIVES
  • REASONS FOR DOING THIS STUDY
  • INTENDED AUDIENCE
  • SCOPE OF THE STUDY
  • METHODOLOGY
  • INFORMATION SOURCES
  • ABOUT THE AUTHOR
  • RELATED BCC RESEARCH REPORTS
  • BCC ONLINE SERVICES
  • DISCLAIMER

Chapter - 2: SUMMARY

  • Table Summary: GLOBAL REVENUE OF KINASE INHIBITORS MARKET, THROUGH 2016
  • Figure Summary: GLOBAL REVENUE OF KINASE INHIBITORS MARKET, 2009-2016

Chapter - 3: OVERVIEW

  • DEFINITIONS
  • ENZYME INHIBITORS
  • KINASE INHIBITORS
  • CLASSIFICATION BY TYPES OF AMINO ACID PHOSPHORYLATION
  • CLASSIFICATION BY SITE OF ACTION

Chapter - 4: REGULATORY ASPECTS

  • MARKET LEADERS AND THEIR PRODUCTS FOR KINASE INHIBITORS
    • Table 13: LEADING MANUFACTURERS AND SUPPLIERS OF RECEPTOR TYROSINE KINASE INHIBITORS
    • Table 14: LEADING MANUFACTURERS AND SUPPLIERS OF NON-RECEPTOR TYROSINE KINASE INHIBITORS
    • Table 15: LEADING MANUFACTURERS AND SUPPLIERS OF MULTI-TARGET TYROSINE KINASE INHIBITORS
    • Table 16: LEADING MANUFACTURERS AND SUPPLIERS OF SERINE AND THREONINE KINASE INHIBITORS
    • Table 17: LEADING MANUFACTURERS AND SUPPLIERS OF ANTIBODY KINASE INHIBITORS

Chapter - 5: NEW DEVELOPMENTS

  • (RECEPTOR) TYROSINE KINASE INHIBITORS (TKIS)
  • (NON-RECEPTOR) TYROSINE KINASE INHIBITORS (TKIS)
  • MULTIKINASE INHIBITORS
  • SERINE/THREONINE KINASE INHIBITOR
  • OTHER KINASE INHIBITOR PRODUCTS UNDER DEVELOPMENT
    • Table 18: CLINICAL TRIALS IN EPIDERMAL GROWTH FACTOR RECEPTOR
    • Table 19: CLINICAL TRIALS IN HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 (HER2) TKIS
    • Table 20: CLINICAL TRIALS IN PLATELET-DERIVED GROWTH FACTOR RECEPTOR (PDGFR) TKIS
    • Table 21: CLINICAL TRIALS IN VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR (VEGFR) TKIS

Chapter - 6: GLOBAL MARKETS

  • MARKET ANALYSIS
  • MARKET SHARE
  • MARKET BY APPLICATIONS
    • Table 29: GLOBAL MARKET FOR KINASE INHIBITORS, THROUGH 2016
    • Figure 1: GLOBAL MARKET FOR KINASE INHIBITORS, 2009-2016

Chapter - 7: EMERGING MARKETS

  • MARKET ANALYSIS
  • MARKET SHARE OF INDUSTRY LEADERS IN EMERGING MARKETS
  • MARKET APPLICATIONS
    • Table 45: EMERGING MARKETS FOR KINASE INHIBITORS, THROUGH 2016
    • Figure 17: EMERGING MARKETS FOR KINASE INHIBITORS, 2009-2016

Chapter - 8: PATENT ANALYSIS

  • PATENTS BY YEAR
  • PATENTS BY CATEGORY
  • PATENTS BY TYPE
  • PATENTS BY COMPANY
  • PATENTS BY COUNTRY
  • PATENTS BY ASSIGNEE
    • Table 61: NUMBER OF SIGNIFICANT PATENTS BY YEAR, 2008 TO END OF FEBRUARY 2012
    • Figure 32: NUMBER OF PATENTS BY YEAR, 2008 TO END OF FEBRUARY 2012
    • Figure 33: NUMBER OF PATENTS BY YEAR, 2008 TO END OF FEBRUARY 2012

Chapter - 9: CURRENT STATUS

  • CANCER AND KINASE INHIBITORS
  • MULTIPLE SINGLE KINASE INHIBITORS VERSUS SINGLE MULTIKINASE INHIBITORS
  • FUTURE DIRECTIONS

Chapter - 10: COMPANY PROFILES

  • ABBOTT LABORATORIES
  • AMGEN INC.
  • ARQULE, INC.
  • ARRAY BIOPHARMA
  • ASTRAZENECA
  • AVEO PHARMACEUTICALS, INC.
  • BAYER AG
  • BRISTOL-MYERS SQUIBB
  • BOEHRINGER INGELHEIM
  • CYTRX CORPORATION
  • EISAI INC
  • ETON BIOSCIENCE, INC.
  • EXELIXIS, INC.
  • GLAXOSMITHKLINE
  • MERCK SERONO SA
  • NOVARTIS INTERNATIONAL AG
  • OSI PHARMACEUTICALS LLC
  • PFIZER
  • ROCHE GROUP
  • S*BIO PTE LTD
  • SANOFI-AVENTIS
  • TAKEDA PHARMACEUTICALS

Chapter - 11: APPENDIX: ABBREVIATIONS

List of Tables

  • Summary Table: GLOBAL REVENUE OF KINASE INHIBITORS MARKET, THROUGH 2016
  • Table 1: CLASSIFICATION OF ENZYME INHIBITORS
  • Table 2: HISTORY OF PROTEIN KINASES
  • Table 3: TYPES OF KINASE INHIBITORS
  • Table 4: ATP COMPETITIVE AND NON-COMPETITIVE INHIBITORS
  • Table 5: TYPES OF SERINE/THREONINE KINASE INHIBITORS
  • Table 6: TYPES OF RECEPTOR TYROSINE KINASE INHIBITORS
  • Table 7: TYPES OF NON-RECEPTOR TYROSINE KINASE INHIBITORS
  • Table 8: CLASSIFICATION OF KINASE INHIBITORS BY SITE OF ACTION
  • Table 9: FDA-APPROVED KINASE INHIBITORS, 2008 TO FEBRUARY 2012
  • Table 10: EMA-APPROVED KINASE INHIBITORS 2008 TO FEBRUARY 2012
  • Table 11: SAFETY ALERTS AND WARNINGS FOR KINASE INHIBITORS 2008 TO FEBRUARY 2012
  • Table 12: NEW DRUG APPLICATIONS OF KINASE INHIBITORS
  • Table 13: LEADING MANUFACTURERS AND SUPPLIERS OF RECEPTOR TYROSINE KINASE INHIBITORS
  • Table 14: LEADING MANUFACTURERS AND SUPPLIERS OF NON-RECEPTOR TYROSINE KINASE INHIBITORS
  • Table 15: LEADING MANUFACTURERS AND SUPPLIERS OF MULTI-TARGET TYROSINE KINASE INHIBITORS
  • Table 16: LEADING MANUFACTURERS AND SUPPLIERS OF SERINE AND THREONINE KINASE INHIBITORS
  • Table 17: LEADING MANUFACTURERS AND SUPPLIERS OF ANTIBODY KINASE INHIBITORS
  • Table 18: CLINICAL TRIALS IN EPIDERMAL GROWTH FACTOR RECEPTOR
  • Table 19: CLINICAL TRIALS IN HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 (HER2) TKIS
  • Table 20: CLINICAL TRIALS IN PLATELET-DERIVED GROWTH FACTOR RECEPTOR (PDGFR) TKIS
  • Table 21: CLINICAL TRIALS IN VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR (VEGFR) TKIS
  • Table 22: CLINICAL TRIALS IN BCR-ABL TYROSINE KINASE INHIBITORS
  • Table 23: CLINICAL TRIALS IN JANUS KINASE (JAK) INHIBITORS
  • Table 24: CLINICAL TRIALS IN SPLEEN TYROSINE KINASE (SYK) INHIBITORS
  • Table 25: CLINICAL TRIALS IN MULTIKINASE INHIBITORS
  • Table 26: CLINICAL TRIALS IN B-RAF KINASE INHIBITORS
  • Table 27: CLINICAL TRIALS IN MAP/MEK INHIBITORS
  • Table 28: CLINICAL TRIALS IN PI3K INHIBITORS
  • Table 29: GLOBAL MARKET FOR KINASE INHIBITORS, THROUGH 2016
  • Table 30: GLOBAL MARKET FOR TYROSINE KINASE INHIBITORS THROUGH 2016
  • Table 31: GLOBAL MARKET FOR RECEPTOR TYROSINE KINASE INHIBITOR THROUGH 2016
  • Table 32: GLOBAL MARKET FOR NON-RECEPTOR TYROSINE KINASE INHIBITOR THROUGH 2016
  • Table 33: GLOBAL MARKET FOR MULTIKINASE TYROSINE INHIBITOR THROUGH 2016
  • Table 34: GLOBAL MARKET FOR SERINE/THREONINE KINASE INHIBITOR THROUGH 2016
  • Table 35: GLOBAL MARKET FOR MONOCLONAL ANTIBODY KINASE INHIBITOR, THROUGH 2016
  • Table 36: RECEPTOR TYROSINE KINASE INHIBITOR MARKET SHARE BY REGION, 2010
  • Table 37: MULTI-TARGET KINASE INHIBITOR MARKET SHARE BY REGION, 2010
  • Table 38: SERINE/THREONINE KINASE INHIBITOR MARKET SHARE BY REGION, 2010
  • Table 39: MONOCLONAL ANTIBODY KINASE INHIBITOR MARKET SHARES BY REGION, 2010
  • Table 40: GLOBAL MARKET FOR KINASE INHIBITORS BY APPLICATIONS, THROUGH 2016
  • Table 41: GLOBAL MARKET FOR KINASE INHIBITORS USED AS ANTINEOPLASTIC AGENTS, THROUGH 2016
  • Table 42: GLOBAL MARKET FOR KINASE INHIBITORS USED AS IMMUNOSUPPRESSANTS, THROUGH 2016
  • Table 43: GLOBAL MARKET FOR KINASE INHIBITORS USED IN AGE-RELATED MACULAR DEGENERATION, THROUGH 2016
  • Table 44: GLOBAL MARKET SHARE OF APPLICATIONS OF KINASE INHIBITORS, 2010
  • Table 45: EMERGING MARKETS FOR KINASE INHIBITORS, THROUGH 2016
  • Table 46: EMERGING MARKETS FOR TYROSINE KINASE INHIBITORS, THROUGH 2016
  • Table 47: EMERGING MARKETS FOR RECEPTOR TYROSINE KINASE INHIBITORS, THROUGH 2016
  • Table 48: EMERGING MARKETS FOR NON-RECEPTOR TYROSINE KINASE INHIBITORS, THROUGH 2016
  • Table 49: EMERGING MARKETS FOR MULTIKINASE TYROSINE KINASE INHIBITORS, THROUGH 2016
  • Table 50: EMERGING MARKETS FOR SERINE/THREONINE KINASE INHIBITORS, THROUGH 2016
  • Table 51: EMERGING MARKETS FOR MONOCLONAL ANTIBODY KINASE INHIBITORS, THROUGH 2016
  • Table 52: SHARE OF RECEPTOR TYROSINE KINASE INHIBITOR MANUFACTURERS IN EMERGING MARKETS, 2010
  • Table 53: SHARE OF MULTI-TARGET KINASE INHIBITOR MANUFACTURERS IN EMERGING MARKETS, 2010
  • Table 54: SHARES OF SERINE/THREONINE KINASE INHIBITOR MANUFACTURERS IN EMERGING MARKETS, 2010
  • Table 55: SHARE OF ANTIBODY KINASE INHIBITOR MANUFACTURERS IN EMERGING MARKETS 2010
  • Table 56: EMERGING MARKETS FOR KINASE INHIBITORS BY APPLICATION, THROUGH 2016
  • Table 57: EMERGING MARKETS FOR KINASE INHIBITORS USED AS ANTINEOPLASTIC AGENTS, THROUGH 2016
  • Table 58: EMERGING MARKETS FOR KINASE INHIBITORS USED AS IMMUNOSUPPRESSANTS, THROUGH 2016
  • Table 59: EMERGING MARKETS FOR KINASE INHIBITORS USED IN AGE-RELATED MACULAR DEGENERATION, THROUGH 2016
  • Table 60: SHARE OF KINASE INHIBITORS IN EMERGING MARKETS BY APPLICATION, 2010
  • Table 61: NUMBER OF SIGNIFICANT PATENTS BY YEAR, 2008 TO END OF FEBRUARY 2012
  • Table 62: PATENTS BY CATEGORY FOR KINASE INHIBITORS 2008 TO END OF FEBRUARY 2012
  • Table 63: PATENTS BY TYPE FOR TYROSINE KINASE INHIBITORS 2008 TO END OF FEBRUARY 2012
  • Table 64: PATENTS BY TYPE FOR SERINE/THREONINE KINASE INHIBITORS, 2008 TO END OF FEBRUARY 2012
  • Table 65: NUMBER OF U.S. PATENTS BY COMPANY FOR INDUSTRIAL ENZYMES, 2008 TO END OF FEBRUARY 2012
  • Table 66: NUMBER OF U.S. PATENTS BY COUNTRY FOR KINASE INHIBITORS, 2008 TO END OF FEBRUARY 2012
  • Table 67: PATENT SHARE BY COUNTRY FOR KINASE INHIBITORS, 2010-2012
  • Table 68: PATENTS BY ASSIGNEE FOR KINASE INHIBITORS, 2008 THROUGH END OF FEBRUARY 2012

List of Figures

  • Summary Figure: GLOBAL REVENUE OF KINASE INHIBITORS MARKET, 2009-2016
  • Figure 1: GLOBAL MARKET FOR KINASE INHIBITORS, 2009-2016
  • Figure 2: GLOBAL MARKET FOR TYROSINE KINASE INHIBITORS 2009-2016
  • Figure 3: GLOBAL MARKET FOR RECEPTOR TYROSINE KINASE INHIBITOR, 2009-2016
  • Figure 4: GLOBAL MARKET FOR NON-RECEPTOR TYROSINE KINASE INHIBITOR, 2009-2016
  • Figure 5: GLOBAL MARKET FOR MULTIKINASE TYROSINE INHIBITOR, 2009-2016
  • Figure 6: GLOBAL MARKET FOR SERINE/THREONINE KINASE INHIBITORS, 2009-2016
  • Figure 7: GLOBAL MARKET FOR MONOCLONAL ANTIBODY KINASE INHIBITOR, 2009-2016
  • Figure 8: RECEPTOR TYROSINE KINASE INHIBITOR MARKET SHARE BY REGION, 2010
  • Figure 9: MULTI-TARGET KINASE INHIBITOR MARKET SHARE BY REGION, 2010
  • Figure 10: SERINE/THREONINE KINASE INHIBITOR MARKET SHARE BY REGION, 2010
  • Figure 11: MONOCLONAL ANTIBODY KINASE INHIBITOR MARKET SHARES BY REGION, 2010
  • Figure 12: GLOBAL MARKET FOR KINASE INHIBITORS BY APPLICATIONS, 2009-2016
  • Figure 13: GLOBAL MARKET FOR KINASE INHIBITORS USED AS ANTINEOPLASTIC AGENTS, 2009-2016
  • Figure 14: GLOBAL MARKET FOR KINASE INHIBITORS USED AS IMMUNOSUPPRESSANTS, 2009-2016
  • Figure 15: GLOBAL MARKET FOR KINASE INHIBITORS USED IN AGE-RELATED MACULAR DEGENERATION, 2009-2016
  • Figure 16: GLOBAL MARKET SHARE OF APPLICATIONS OF KINASE INHIBITORS, 2010
  • Figure 17: EMERGING MARKETS FOR KINASE INHIBITORS, 2009-2016
  • Figure 18: EMERGING MARKETS FOR TYROSINE KINASE INHIBITORS, 2009-2016
  • Figure 19: EMERGING MARKETS FOR RECEPTOR TYROSINE KINASE INHIBITORS, 2009-2016
  • Figure 20: EMERGING MARKETS FOR MULTIKINASE TYROSINE KINASE INHIBITORS, 2009-2016
  • Figure 21: EMERGING MARKETS FOR SERINE/THREONINE KINASE INHIBITOR, 2009-2016
  • Figure 22: EMERGING MARKETS FOR MONOCLONAL ANTIBODY KINASE INHIBITORS, 2009-2016
  • Figure 23: SHARE OF RECEPTOR TYROSINE KINASE INHIBITOR MANUFACTURERS IN EMERGING MARKETS, 2010
  • Figure 24: SHARES OF MULTI-TARGET KINASE INHIBITOR MANUFACTURERS IN EMERGING MARKETS, 2010
  • Figure 25: SHARES OF SERINE/THREONINE KINASE INHIBITOR MANUFACTURERS IN EMERGING MARKETS, 2010
  • Figure 26: SHARES OF SERINE/THREONINE KINASE INHIBITOR MANUFACTURERS IN EMERGING MARKETS, 2010
  • Figure 27: EMERGING MARKETS FOR KINASE INHIBITORS BY APPLICATION, 2009-2016
  • Figure 28: EMERGING MARKETS FOR KINASE INHIBITORS USED AS ANTINEOPLASTIC AGENTS, 2009-2016
  • Figure 29: EMERGING MARKETS FOR KINASE INHIBITORS USED AS IMMUNOSUPPRESSANTS, 2009-2016
  • Figure 30: EMERGING MARKETS FOR KINASE INHIBITORS USED IN AGE-RELATED MACULAR DEGENERATION, 2009-2016
  • Figure 31: SHARE OF KINASE INHIBITORS IN EMERGING MARKETS BY APPLICATION, 2010
  • Figure 32: NUMBER OF PATENTS BY YEAR, 2008 TO END OF FEBRUARY 2012
  • Figure 33: NUMBER OF PATENTS BY YEAR, 2008 TO END OF FEBRUARY 2012
  • Figure 34: PATENTS BY CATEGORY FOR KINASE INHIBITORS 2008 TO END OF FEBRUARY 2012
  • Figure 35: PATENTS BY TYPE FOR TYROSINE KINASE INHIBITORS 2008 TO END OF FEBRUARY 2012
  • Figure 36: PATENTS BY TYPE FOR SERINE/THREONINE KINASE INHIBITORS, 2008 TO END OF FEBRUARY 2012
  • Figure 37: NUMBER OF U.S. PATENTS BY COUNTRY FOR KINASE INHIBITORS, 2008 TO END OF FEBRUARY 2012
  • Figure 38: PATENT SHARES BY COUNTRY FOR KINASE INHIBITORS, 2010 - 2012
  • Figure 39: PATENT SHARES BY COUNTRY FOR KINASE INHIBITORS, 2008-2012
Back to Top